Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Mackensen

Showing results (181-190 of 196) with videos related to

Pageof 20
Sort By:
Nature Medicine|October 23, 2023
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trialAndreas Mackensen, John B A G Haanen, Christian Koenecke, et al.
Science Immunology|August 8, 2017
Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironmentGordon F Heidkamp, Jil Sander, Christian H K Lehmann, et al.
Nature Medicine|January 7, 2026
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trialFabian Müller, Melanie Hagen, Andreas Wirsching, et al.
Nature Communications|May 23, 2026
Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cellsAleix Rius Rigau, Meilin Xu, Ziyuan Liu, et al.
Nature Medicine|February 5, 2026
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseasesMarco Becilli, Markus Metzler, Claudia Bracaglia, et al.
Cancers|October 27, 2022
Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA ConsortiumFlorian Lüke, Florian Haller, Kirsten Utpatel, et al.
The Lancet. Rheumatology|November 14, 2024
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case seriesJanina Auth, Fabian Müller, Simon Völkl, et al.
Cell Metabolism|September 20, 2016
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK CellsAlmut Brand, Katrin Singer, Gudrun E Koehl, et al.
Leukemia|February 19, 2021
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2024
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of GermanyMarkus Krebs, Florian Haller, Silvia Spörl, et al.
Pageof 20

Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Nature Medicine|October 23, 2023
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trialAndreas Mackensen, John B A G Haanen, Christian Koenecke, et al.
Science Immunology|August 8, 2017
Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironmentGordon F Heidkamp, Jil Sander, Christian H K Lehmann, et al.
Nature Medicine|January 7, 2026
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trialFabian Müller, Melanie Hagen, Andreas Wirsching, et al.
Nature Communications|May 23, 2026
Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cellsAleix Rius Rigau, Meilin Xu, Ziyuan Liu, et al.
Nature Medicine|February 5, 2026
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseasesMarco Becilli, Markus Metzler, Claudia Bracaglia, et al.
Cancers|October 27, 2022
Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA ConsortiumFlorian Lüke, Florian Haller, Kirsten Utpatel, et al.
The Lancet. Rheumatology|November 14, 2024
CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case seriesJanina Auth, Fabian Müller, Simon Völkl, et al.
Cell Metabolism|September 20, 2016
LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK CellsAlmut Brand, Katrin Singer, Gudrun E Koehl, et al.
Leukemia|February 19, 2021
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trialChristoph Röllig, Hubert Serve, Richard Noppeney, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2024
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of GermanyMarkus Krebs, Florian Haller, Silvia Spörl, et al.
Pageof 20